Here's something you might be interested in.
The Food and Drug Administration (FDA) announced today (Friday, April 25) that it wants more information on Mipomersen, a potential cholesterol-lowering drug being developed by San Diego biotech Isis Pharmaceuticals along with Genzyme. The agency wants more data on two ongoing studies. The demand should delay the product another year. With 45 minutes left in Friday trading, Isis stock is down 28.57 percent to $12.00.
The Food and Drug Administration (FDA) announced today (Friday, April 25) that it wants more information on Mipomersen, a potential cholesterol-lowering drug being developed by San Diego biotech Isis Pharmaceuticals along with Genzyme. The agency wants more data on two ongoing studies. The demand should delay the product another year. With 45 minutes left in Friday trading, Isis stock is down 28.57 percent to $12.00.